Abstract 51P
Background
Conversion therapy for biliary tract cancer has attracted increasing interest in recent years. Camrelizumab plus oxaliplatin-based chemotherapy has shown clinical activity as the first-line treatment for patients (pts) with advanced BTC. HAIC with oxaliplatin and 5-fluorouracil (HAIC-FO) could improve the objective response rate (ORR) in advanced perihilacholangiocarcinoma and GBC. This study aims to evaluate the efficacy and safety of camrelizumab in combination with HAIC-FO as conversion therapy in pts with initially unresectable advanced eCCA and GBC.
Methods
This ongoing phase II study enrolled pts with pathologically confirmed initially unresectable advanced eCCA or GBC to receive intravenous camrelizumab (200 mg, day 1, q2w) plus HAIC with oxaliplatin (40 mg/m2 for 2 h, days 1-3, q4w) and 5-fluorouracil (800 mg/m2 for 22 h, days 1-3, q4w). Treatment was continued until potential resectability could be achieved, disease progression, intolerable toxicity, or withdrawal of consent. The primary endpoint was ORR per RECIST v1.1.The secondary endpoint was organ-specific ORR and safety.
Results
Between June 15, 2021 and April 15, 2024, 42 pts were enrolled and treated. Of these, 34 pts completed at least 4 cycles of conversion therapy and 7 pts still under treatment. The median follow-up time was 12.8 months. The ORR was 47.0% and the disease control rate was 61.8%. 14 pts underwent surgery after successful conversion therapy. The conversion rate was 41.2% and the R0 resection rate was 92.8%. 5(11.9%) of 42 pts had treatment-related adverse event (TRAEs) that were Grade 3 or 4. No Grade 3 or 4 TRAEs occurred after surgery. Table: 51P
Baseline characteristic, response | |
Median age (range), y | 64 (35-75) |
Male/Female | 19/23 |
eCCA/GBC | 29/13 |
Remote metastasis exists,n (%) | 10 (23.8%) |
ORR/DCR, % | 47.0% / 61.8% |
Organ-specific ORR, % | 64.7% |
6-m PFS,% | 58.8% |
6-m OS,% | 91.2% |
Conclusions
These promising preliminary results may suggest camrelizumab in combination with HAIC-FO as an effective therapeutic regimen for initially unresectable advanced eCCA and GBC.
Clinical trial identification
ChiCTR2100044629.
Editorial acknowledgement
Legal entity responsible for the study
W. Zhai.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
55P - Subsequent anticancer therapy (SAT) analysis from 3-year follow-up of the phase III TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in biliary tract cancer (BTC)
Presenter: Arndt Vogel
Session: Poster session 13
56P - Multi-omic profiling in cholangiocarcinoma to enable scientific advancement within the DKFZ/NCT/DKTK MASTER study
Presenter: Federico Nichetti
Session: Poster session 13
57P - Integrative analysis of the genomic and transcriptomic landscape identifies ciliary genes as a therapeutic target in bile duct cancer
Presenter: Pietro Carotenuto
Session: Poster session 13
58P - Efficacy and safety of liposomal irinotecan (nal-IRI) plus fluorouracil (5-FU) and leucovorin (LV) versus 5-FU/LV alone for advanced biliary tract cancer (BTC) after progression on gemcitabine-based therapy: A pooled analysis of the NIFTY and NALIRICC trials
Presenter: Changhoon Yoo
Session: Poster session 13
59P - Prognostic score to predict recurrence after pancreaticoduodenectomy for ampullary carcinoma: Results from the French prospective FFCD cohort
Presenter: Gael Roth
Session: Poster session 13
60P - Baseline characteristics and molecular testing of patients with IDH1-mutated cholangiocarcinoma: Initial results from the phase IIIb ProvIDHe study
Presenter: Lorenza Rimassa
Session: Poster session 13
61P - Addressing racial disparities in clinical trials in cholangiocarcinoma
Presenter: Abhinav Vyas
Session: Poster session 13
Resources:
Abstract
62TiP - HERIZON-BTC-302: A phase III study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line (1L) treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC)
Presenter: Teresa Macarulla Mercade
Session: Poster session 13
240P - Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in older patients (pts) with HR+/HER2− early breast cancer (EBC) in NATALEE
Presenter: Michael Untch
Session: Poster session 13